Skip to content

A Registered Cohort Study on Amyotrophic Lateral Sclerosis

A Registered Cohort Study on Amyotrophic Lateral Sclerosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04008329
Enrollment
2000
Registered
2019-07-05
Start date
2019-07-05
Completion date
2059-07-31
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Keywords

amyotrophic lateral sclerosis, natural history, genetics, prognostic factors

Brief summary

Amyotrophic lateral sclerosis (ALS) is a kind of motor neuron degeneration disorder without effective therapy. This registered cohort study will provide further insights into the clinical course of ALS, and investigate disease-relative risk factors and the genetic background of Chinese ALS patients.

Detailed description

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND), which is characterized with highly clinical heterogeneity and no effective treatment is available now. The purpose of this registered cohort is to observe the natural history of ALS patients in China, and then identify some factors correlated with disease progression. Besides, ALS-related gene mutations will be screened and explore novel disease causing gene as well.

Interventions

None listed

Sponsors

First Affiliated Hospital of Fujian Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Amyotrophic Lateral Sclerosis patients fulfilling the El Escorial criteria (including definite, probable and possible) * Progressive muscular atrophy * Primary lateral sclerosis * Progressive bulbar palsy

Exclusion criteria

* History of serious head trauma or neuropsychiatric disease * Decline to participate

Design outcomes

Primary

MeasureTime frameDescription
Age at death10 yearsthe time when patient die
Age of endotracheal intubation or tracheotomy10 yearsthe time for the patient accepted endotracheal intubation or tracheotomy

Countries

China

Contacts

Primary ContactQi-Jie Zhang, PhD
qijiezhang86@fjmu.edu.cn086-591-87982772

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026